Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. (EIDX) is a publicly traded company in the Unknown sector. Across all available filings, 12 corporate insiders have executed 216 transactions totaling $466.9M, demonstrating a bullish sentiment with $412.5M in net insider flow. The most recent transaction on Jan 26, 2021 involved a purchase of 14,428,836 shares valued at $0.
EIDX Insider Activity Summary
Who Is Buying EIDX Stock?
No significant insider buying has been recorded for EIDX in the recent period.
Who Is Selling EIDX Stock?
No significant insider selling has been recorded for EIDX in the recent period.
Is Eidos Therapeutics, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for EIDX is bullish with an Insider Alignment Score of 94/100 and a net flow of $412.5M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
EIDX Frequently Asked Questions
Understanding EIDX Insider Activity
Insider trading at Eidos Therapeutics, Inc. (EIDX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 12 insiders are actively trading EIDX stock, having executed 216 transactions in the past 90 days. The most active insider is Ali J. Satvat (Executive), who has made 12 transactions totaling $119.8M.
Related Tools
Track Eidos Therapeutics, Inc. Insider Activity
Get notified when executives and directors at EIDX file new Form 4 transactions